Localization of Hidden Insulinomas with ⁶⁸Ga-DOTA-Exendin-4 PET/CT: A Pilot Study

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

The researchers aimed at determining whether novel PET/CT imaging with [Nle(14),Lys(40)(Ahx-DOTA-(68)Ga)NH2]exendin-4 ((68)Ga-DOTA-exendin-4) is feasible and sensitive in detecting benign insulinomas.

Who Took Part

According to the abstract, 5 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

(68)Ga-DOTA-exendin-4 PET/CT and (111)In-DOTA-exendin-4 SPECT/CT were performed in a randomized cross-over order on 5 patients with endogenous hyperinsulinemic hypoglycemia.

How the Study Was Run

The design is described as randomized, crossover and pilot.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

It is described as a pilot, a small early test of whether a larger Exenatide study would be practical.

The gold standard for comparison was the histologic diagnosis after surgery.

What Was Measured

Topics PubMed links to this paper include Diagnostic Imaging, Exenatide, Gallium Radioisotopes, Glucose, Heterocyclic Compounds, 1-Ring, Immunohistochemistry and Insulinoma.

The authors tagged it with the keywords 68Ga, exendin-4 and glucagon-like peptide-1 receptor targeting.

What This Means in Plain Language

The paper is a randomized, crossover and pilot study of Exenatide in 5 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Exenatide compound page, all human trials.